Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study
AGTC patient advocacy executive director and director of patient enrollment to speak at Clinical Trials in Rare Diseases Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
WINSTON SALEM, N.C. , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Greater Gift of Winston Salem , a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for
View HTML
Toggle Summary AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
- Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human
View HTML
Toggle Summary AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion
-AGTC patient advocacy executive director will address genetic testing and gene therapy for the treatment of rare retinal diseases- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC to Participate at Upcoming Investor Conferences
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Visionary science for life changing cures.